Abstract
Immune checkpoint inhibitors (ICIs) have become new research hotspots in
the treatment of non-small cell lung cancer, but the efficacy and safety
of immunotherapy for patients with chronic viral infection are still
unclear, because existing clinical trials often exclude those patients.